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Background and objectives: Despite reductions in prevalence in recent years,
tobacco smoking remains one of the main preventable causes of ill-health and
premature death worldwide. This paper reviews the extent and nature of harms
caused by smoking, the beneﬁts of stopping, patterns of smoking, psychologi-
cal, pharmacological and social factors that contribute to uptake and mainte-
nance of smoking, the effectiveness of population and individual level
interventions aimed at combatting tobacco smoking, and the effectiveness of
methods used to reduce the harm caused by continued use of tobacco or nico-
tine in some form.
Results and conclusions: Smoking behaviour is maintained primarily by the
positive and negative reinforcing properties of nicotine delivered rapidly in a
way that is affordable and palatable, with the negative health consequences
mostly being sufﬁciently uncertain and distant in time not to create sufﬁcient
immediate concern to deter the behaviour. Raising immediate concerns about
smoking by tax increases, social marketing and brief advice from health pro-
fessionals can increase the rate at which smokers try to stop. Providing beha-
vioural and pharmacological support can improve the rate at which those quit
attempts succeed. Implementing national programmes containing these compo-
nents are effective in reducing tobacco smoking prevalence and reducing
smoking-related death and disease.
Keywords: smoking; tobacco; addiction
Introduction
The continued popularity of tobacco smoking appears to defy rational explanation.
Smokers mostly acknowledge the harm they are doing to themselves and many report
that they do not enjoy it – yet they continue to smoke (Fidler & West, 2011; Ussher,
Brown, Rajamanoharan, & West, 2014). The reason is that nicotine from cigarettes gen-
erates strong urges to smoke that undermine and overwhelm concerns about the nega-
tive consequences of smoking, and the resolve not to smoke in those trying to stop
(West & Shiffman, 2016). Progress is being made in many countries in reducing smok-
ing prevalence but it remains one of the main causes of ill health and premature death
worldwide (Gowing et al., 2015).
This paper provides a broad overview of smoking in terms of: the health effects,
beneﬁts of stopping, prevalence and patterns of use, psychological, pharmacological
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and social factors leading to uptake and maintenance of the behaviour, effectiveness of
population level and individual level interventions to combat it, and methods used to
reduce the harm despite continued use of tobacco or nicotine.
Deﬁnitions of smoking and smoking cessation
Tobacco smoking consists of drawing into the mouth, and usually the lungs, smoke
from burning tobacco (West & Shiffman, 2016). The type of product smoked is most
commonly cigarettes, but can also include cigarillos, cigars, pipes or water pipes.
‘Smokeless’ tobacco is also popular in some parts of the world. This typically involves
using tobacco preparations for chewing, snifﬁng into the nose or placing as a wad in
the mouth between the cheeks and gums (Critchley & Unal, 2003). Smokeless tobacco
use has features that are similar to smoking and can carry signiﬁcant health risks
(Critchley & Unal, 2003); however, this article focuses on smoked tobacco only as this
has been the subject of by far the largest volume of research and is the most harmful
form of tobacco use.
Stopping smoking usually involves an intention not to smoke any more cigarettes
from a given point in time (a ‘quit attempt’), followed by self-conscious resistance of
urges to smoke resulting in a period of abstinence. If someone making a quit attempt
smokes one or more cigarettes on an occasion but then resumes abstinence, this is usu-
ally termed a ‘lapse’. If this person resumes smoking on a regular basis s/he is said to
have ‘relapsed’. ‘Short-term abstinence’ is commonly deﬁned in terms of achieving up
to 4 weeks of abstinence. ‘Long-term abstinence’ often refers to abstinence for at least
6 months but more typically involves abstinence for at least 12 months. There is no
agreed criterion for deciding when someone has ‘stopped smoking’ so it is essential
when using the term to be clear about how long the abstinence period has been.
Health impact of smoking and the beneﬁts of stopping
Tobacco smoking increases the risk of contracting a wide range of diseases, many of
which are fatal. Stopping smoking at any age is beneﬁcial compared with continuing to
smoke. For some diseases, the risk can be reversed while for others the risk is approxi-
mately frozen at the point when smoking stopped.
Health impact of smoking
Table 1 lists the main causes of death from smoking. Tobacco smoking is estimated to
lead to the premature death of approximately 6 million people worldwide and 96,000 in
the UK each year (Action on Smoking and Health, 2016b; World Health Organization,
2013). A ‘premature death from smoking’ is deﬁned as a death from a smoking-related
disease in an individual who would otherwise have died later from another cause. On
average, these premature deaths involve 10 years of life years lost (US Department of
Health and Human Services, 2004). Many of these deaths occur in people who have
stopped smoking but whose health has already been harmed by smoking. It also hap-
pens to be the case that smokers who do not stop smoking lose an average of 10 years
of life expectancy compared with never-smokers and they start to suffer diseases of old
age around 10 years earlier than non-smokers (Jha & Peto, 2014).
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Most smoking-related deaths arise from cancers (mainly lung cancer), respiratory
disease (mainly chronic obstructive pulmonary disease – COPD), and cardiovascular
disease (mainly coronary heart disease) (Action on Smoking and Health, 2016b). Smok-
ing is an important risk factor for stroke, blindness, deafness, back pain, osteoporosis,
and peripheral vascular disease (leading to amputation) (US Department of Health and
Human Services, 2004). After the age of 40, smokers on average have higher levels of
pain and disability than non-smokers (US Department of Health and Human Services,
2004).
Smoking in both women and men reduces fertility (Action on Smoking and Health,
2013). Smoking in pregnancy causes underdevelopment of the foetus and increases the
risk of miscarriage, neonatal death, respiratory disease in the offspring, and is probably
a cause of mental health problems in the offspring (Action on Smoking and Health,
2013).
People used to think that smoking was protective against Alzheimer’s disease but
we now know that the opposite is the case: it is a major risk factor for both Alzhei-
mer’s and vascular dementia (Ferri et al., 2011; US Department of Health and Human
Services, 2004).
There is a positive association between average daily cigarette consumption and risk
of smoking-related disease, but in the case of cardiovascular disease the association is
non-linear, so that low levels of cigarette consumption carry a higher risk than would
be expected from a simple linear relationship (US Department of Health and Human
Services, 2004).
Tobacco smoke contains biologically signiﬁcant concentrations of known carcino-
gens as well as many other toxic chemicals. Some of these, including a number of
tobacco-speciﬁc nitrosamines (particularly NNK and NNN) are constituents of tobacco,
largely as a result of the way it is processed, while others such as benzopyrine result
from combustion of tobacco (Action on Smoking and Health, 2014b). These chemicals
form part of the particulate matter in smoke. Tobacco smoke also contains the gas, car-
bon monoxide (CO). CO is a potent toxin, displacing oxygen from haemoglobin mole-
cules. However, acutely the amount of CO in tobacco smoke is too small to lead to
hypoxia and the body produces increased numbers of red blood cells to compensate.
The nicotine in tobacco smoke may cause a small part of the increase in cardiovas-
cular disease but none or almost none of the increase in risk of respiratory disease or
cancer (Benowitz, 1997, 1998). It is the other components of cigarette smoke that do
almost all the damage. It has been proposed on the basis of studies with other species
that nicotine damages the adolescent brain but there is no evidence for clinically
Table 1. Main causes of death from tobacco smoking and beneﬁts of stopping.
Cause of death from smoking Beneﬁt of stopping smoking
Coronary heart disease and
stroke
Preventable if cessation occurs in early adulthood; at least
partially reversible thereafter
Cancers of the lung and upper
airways
Preventable if cessation occurs in early adulthood; further
increase in risk prevented thereafter
Chronic obstructive
pulmonary disease
Preventable if cessation occurs in early adulthood; further
decline in lung function slowed thereafter
Miscarriage and
underdevelopment of foetus
Preventable if cessation occurs early in pregnancy; risk is
mitigated by stopping at any time in pregnancy
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signiﬁcant deﬁcits in cognition or emotion in adults who smoked during adolescence
and then stopped (US Department of Health and Human Services, 2004).
Exposure to second-hand smoke carries a signiﬁcant risk for both children and
adults. Thus, non-smokers who are exposed to a smoky environment have an increased
risk of cancer, heart disease and respiratory disease (Action on Smoking and Health,
2014a).
Beneﬁts of stopping smoking
Table 1 lists the main beneﬁts of stopping smoking. Smokers who stop before their
mid-30s have approximately the same life expectancy as never smokers (Doll, Peto,
Boreham, & Sutherland, 2004; Pirie, Peto, Reeves, Green, & Beral, 2013). After the
age of 35 years or so, stopping smoking recovers 2–3 months of healthy life expectancy
for every year of smoking avoided, or 4–6 h for every day (Jha & Peto, 2014).
Stopping smoking has different effects on different smoking-related diseases. Excess
risk of heart attack caused by smoking reduces by 50% within 12 months of stopping
smoking. Stopping smoking returns the rate of decline in lung function to the normal
age-related decline, but does not reverse this; it reduces the frequency of ‘exacerbations’
(acute attacks of breathing difﬁculty resulting in death or hospitalisation) in COPD
patients (US Surgeon General, 1990). Stopping smoking ‘freezes’ the risk of smoking-
related cancers at the level experienced when stopping occurs but does not decrease it
in absolute terms (US Surgeon General, 1990).
Smokers who stop show reduced levels of stress and mood disorder than those who
continue (Royal College of Physicians and Royal College of Psychiatrists, 2013). They
also report higher levels of happiness and life satisfaction than those who continue
(Shahab & West, 2009, 2012). This suggests that smoking may harm mental health,
though other explanations cannot be ruled out on the current evidence.
Prevalence and patterns of smoking
Smoking prevalence
There are estimated to be approximately 1 billion tobacco smokers worldwide (Eriksen,
Mackay, & Ross, 2013), amounting to approximately 30% of men and 7% of women
(Gowing et al., 2015).
Cigarette smoking prevalence in Great Britain was estimated to be 16.9% in 2015,
the most recent year for which ﬁgures are available at the time of writing: slightly
lower in women than men (Ofﬁce of National Satistics, 2016). Smoking in Great Bri-
tain has declined by 0.7 percentage points per year since 2001 (from 26.9% of adults in
2001). In Australia, daily cigarette smoking has declined by 0.6 percentage points per
year over a similar time period (from 22.4% of adults aged 18 + years in 2001 to
14.5% in 2015) (Australian Bureau of Statistics, 2015). However, international compar-
isons are confused by different countries using a different deﬁnition of what counts as
being a smoker, and different methods for assessing prevalence. Australia only counts
daily smokers in their headline ﬁgures. The situation in the US is even more mislead-
ing. The headline prevalence ﬁgure for the US is below 16%, but this does not include
occasional smokers and people who smoke cigarillos which are essentially cigarettes in
all but name and which have become increasingly popular in recent years. So the ﬁgure
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for prevalence that is most comparable to the ﬁgure for Great Britain is 20% (Jamal,
2016).
With the above caveats in mind, the ﬁgures in Table 2 for smoking prevalence in
world regions in men and women provide very broad estimates (Gowing et al., 2015).
Most noteworthy is that smoking prevalence in men is more than four times that in
women globally but that the difference is much less in most parts of Europe, and that
Eastern Europe as a whole has the highest smoking prevalence of any region in the
world.
Smoking patterns
The most common age of ﬁrst trying a cigarette in countries that have been studied is
10–15 years (Action on Smoking and Health, 2015b; Talip, Murang, Kiﬂi, & Naing,
2016); take up of regular smoking usually continues up to early 20s (Dierker et al., 2008).
Average daily cigarette consumption among smokers in the US and UK has
declined steadily since the 1970s. In the UK, it is currently 11 cigarettes per day, and
non-daily smoking is very rare (Action on Smoking and Health, 2016c; Jarvis, Giovino,
O’Connor, Kozlowski, & Bernert, 2014). Smokers take in an average of 1–1.5 mg of
nicotine per cigarette (US Department of Health Human Services, 2014). The US ﬁg-
ures on patterns of smoking are distorted by not counting ‘cigarillos’ and other smoked
tobacco products which are used very much like cigarettes, whose prevalence has
increased in recent years (Jamal et al., 2015). The reduction in daily cigarette consump-
tion has not been accompanied by a reduction in daily nicotine intake (Jarvis et al.,
2014). This could be due to the use of other smoked tobacco products (in the case of
the US) or smokers smoking their cigarettes more intensively (taking more, deeper or
longer puffs).
Smokers in England spend an average of £23 per week on cigarettes and this ﬁgure
is slowly rising (West & Brown, 2015). In the UK, hand-rolled cigarettes have become
Table 2. Estimates of tobacco smoking prevalence in world regions.
Region
Male prevalence
%
Female prevalence
%
Overall prevalence
%
Africa 23 3 13
Caribbean Central and Northern
America
20 4 13
South America 30 15 21
Central Southern and Western Asia 37 4 23
Eastern and South-eastern Asia 45 4 24
Eastern Europe 42 22 31
Northern Europe 28 22 27
Southern Europe 35 24 28
Western Europe 33 24 29
Oceania 43 19 30
World 32 7 23
Note: Current smoking of any tobacco product, adults aged 15 years and older, age-standardised rate, by gen-
der. ‘Tobacco smoking’ includes cigarettes, cigars, pipes or any other smoked tobacco products. ‘Current
smoking’ includes both daily and non-daily or occasional smoking. From Gowing et al. (2015).
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increasingly popular with 34% of smokers currently reporting use of these products
(Action on Smoking and Health, 2016c). Men and people in more deprived socio-
economic groups are more likely to smoke hand-rolled cigarettes (Action on Smoking
and Health, 2016c).
In most countries, there are strong negative associations between smoking preva-
lence and educational level, afﬂuence and mental health; and positive associations with
alcohol use disorder and substance use disorder (Action on Smoking and Health,
2016a, 2016c; Royal College of Physicians and Royal College of Psychiatrists, 2013;
Talati, Keyes, & Hasin, 2016). In the UK, average daily cigarette consumption is higher
for men than women, and higher in smokers in more deprived socio-economic groups
and those with mental health problems (Action on Smoking and Health, 2016c).
Psychological, pharmacological and social factors involved in smoking and
smoking cessation
The natural history of smoking can be modelled as states and factors that inﬂuence the
transition between these. Figure 1 shows transitions that have been researched – the
variables identiﬁed in the diagram are listed descriptively without attempting to explain
how they may be connected.
Smoking initiation
Important factors predicting initiation in western societies are: having friends who
smoke, having parents who smoke, low social grade, tendency to mental health prob-
lems and impulsivity (Action on Smoking and Health, 2015b). Transition to daily
Figure 1. Factors associated with transitions in the natural history of smoking (parentheses indi-
cate negative associations).
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smoking follows a highly variable pattern sometimes being very rapid and sometimes
taking several years (Schepis & Rao, 2005). Important factors predicting transition to
regular smoking are: having friends who smoke, weak academic orientation, low paren-
tal support, pro-smoking attitudes, drinking alcohol and low socio-economic status
(Action on Smoking and Health, 2015b).
Smoking initiation has a ‘heritability’ (the proportion of variance in a characteristic
that is attributable to genetic rather than environmental variance) of approximately 30–
50% in western societies (Vink, Willemsen, & Boomsma, 2005). This means that differ-
ences in genetic make-up account for almost half of the difference in likelihood of start-
ing smoking between individuals. This does not mean that environmental factors do not
also play a crucial role as is evident from the very large decline in smoking initiation
since the 1970s in many western countries.
The heritability of cigarette addiction (as distinct from smoking) is approximately
70–80% in western societies (Vink et al., 2005). Cigarette addiction here refers to the
extent to which someone experiences a strong need to smoke. It is usually indexed by a
combination of number of cigarettes per day and time from waking to smoking the ﬁrst
cigarette of the day (Kozlowski, Porter, Orleans, Pope, & Heatherton, 1994). It can also
be indexed by the self-reported strength of urges to smoke (Fidler, Shahab, & West,
2011). Heritability of cigarette addiction, as indexed by failure of attempts to stop, is
higher than the heritability for smoking and for initiation of smoking. This suggests that
differences in genetic inheritance play a larger role in being able to stop smoking than
in starting to smoke.
Cigarette addiction
Cigarette addiction stems from the fact that smoking provides highly controllable doses
of the drug, nicotine, rapidly to the brain in a form that is accessible, affordable and
palatable (West, 2009; West & Shiffman, 2016). Nicotine provided more slowly, for
example by the nicotine transdermal patch, is much less addictive. It is possible that
one or more mono-amine oxidase inhibitors in cigarette smoke add to, or synergise, the
addictive properties of nicotine (Hogg, 2016).
The psychopharmacology of cigarette addiction is complex and far from fully
understood. The following paragraphs summarise the current narrative.
Nicotine resembles the naturally occurring neurotransmitter, acetylcholine, sufﬁ-
ciently to attach itself to a subset of neuronal receptors for this neurotransmitter in the
brain. These are called ‘nicotinic acetylcholine receptors’. When it does this with recep-
tors in the ventral tegmental area in the midbrain, it causes an increased rate of ﬁring of
the nerves projecting forward from that area to another part of the brain called the
nucleus accumbens. This causes release of another neurotransmitter called dopamine in
the nucleus accumbens.
Dopamine release and uptake by neurones in the nucleus accumbens is believed to
be central to all addictive behaviours. It acts as a neural ‘teaching signal’ which causes
the brain to form an association between the current situation as perceived and the
impulse to engage in whatever action immediately preceded this release. In the case of
smoking, this creates an urge to smoke in situations in which smoking frequently
occurs. These are often referred to as ‘cue-driven smoking urges’ or ‘situational
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cravings’ (West, 2009; West & Shiffman, 2016). This explains why even non-daily
smokers often ﬁnd it difﬁcult to stop smoking altogether.
Repeated ingestion of nicotine from cigarettes causes changes to the functioning of
the ventral tegmental area and nucleus accumbens such that when brain concentrations
of nicotine are lower than usual, there is an abnormally low level of neural activity in
these regions. This leads to feelings of need for behaviours that have in the past
restored normal functioning, typically smoking. This feeling of need can be thought of
as a kind of ‘nicotine hunger’, also called ‘background craving’ (West, 2009; West &
Shiffman, 2016). This is probably why time between waking and ﬁrst cigarette of the
day is a useful predictor of difﬁculty stopping smoking (Vangeli, Stapleton, Smit, Bor-
land, & West, 2011). So ‘cue-driven smoking urges’ and ‘nicotine hunger’ are impor-
tant factors contributing to smoking behaviour and thought to be the primary
mechanisms underpinning cigarette addiction (West, 2009; West & Shiffman, 2016).
When smokers abstain from cigarettes, within a few hours many of them start to
experience nicotine withdrawal symptoms. Withdrawal symptoms from a drug are tem-
porary symptoms that arise when the drug dose is reduced or use is terminated. They
arise from neural adaptation to the presence of the drug in the central nervous system.
For smoking, the most common early onset symptoms are: irritability, restlessness and
difﬁcult concentrating. Depression and anxiety have also been observed in some smok-
ers. These symptoms typically last 1 to 4 weeks (West, 2009; West & Shiffman, 2016).
After a day or two of stopping smoking, many smokers experience other symptoms:
increased appetite, constipation, mouth ulcers, cough, and weight gain. Increased appe-
tite tends to last for at least 3 months; weight gain (averaging around 6 kg) tends to be
permanent; other symptoms tend to last a few weeks. The increased appetite, weight
gain and constipation arise from termination of nicotine intake but the others are proba-
bly related to other effects of stopping smoking (West, 2009; West & Shiffman, 2016).
Any of the above effects of abstinence may in individual cases promote resumption
of smoking following a quit attempt but statistically the association is inconsistent and
weak; the main factors driving relapse appear to be cue-driven smoking urges and nico-
tine hunger (Fidler & West, 2011; West, 2009; West & Shiffman, 2016).
Many smokers report that smoking helps them cope with stress and increases their
ability to concentrate. However, this appears to be because when they go for a period
without smoking they experience nicotine withdrawal symptoms that are relieved by
smoking. Long-term smokers who stop report lower levels of stress than when they
were smoking and no reduction in ability to concentrate (West, 2009; West & Shiffman,
2016).
It is commonly thought that smokers with mental health problems are using cigar-
ettes to ‘self-medicate’ or treat their psychological symptoms. However, the evidence
indicates that neither nicotine nor smoking improves psychological symptoms, and
people with serious mental health disorders who stop smoking do not experience a
worsening of mental health. In fact some studies have found an improvement (Royal
College of Physicians and Royal College of Psychiatrists, 2013).
Smoking cessation
For most smokers, cessation requires a determined attempt to stop and then sufﬁcient
resolve in the following weeks and months to overcome what are often powerful urges
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to smoke. Factors that predict quit attempts differ from those that predict the success of
those attempts (Vangeli et al., 2011). Approximately 5% of unaided quit attempts suc-
ceed for at least 6 months (Hughes, Keely, & Naud, 2004). Relapse after this point is
estimated to be around 50% over subsequent years (Stapleton & West, 2012).
The most common self-reported reasons for smoking are stress relief and enjoyment,
with around half of smokers reporting these smoking motives. Weight control, aiding
concentration and socialising are also quite commonly cited (Fidler & West, 2009).
Smoking for supposed stress relief, improved concentration, weight control or other
functions has not been found to be related to attempts to stop or success of attempts to
stop (Fidler & West, 2009). Smokers who report enjoying smoking are less likely to try
to stop but not less likely to succeed if they do try (Fidler & West, 2011). In addition,
having a positive smoker identity (liking being a smoker) predicts not trying to quit,
over and above enjoyment of smoking (Fidler & West, 2009).
No clear association has been found between the number of times smokers have
tried to stop in the past and their chances of success the next time they try (Vangeli
et al., 2011). However, having tried to stop in the past few months is predictive of fail-
ure of the next quit attempt (Zhou et al., 2009). Belief in the harm caused by smoking
is predictive of smokers making quit attempts but not the success of those attempts
(Vangeli et al., 2011).
Some clinical studies have found that women were less likely to succeed in quit
attempts than men but large population studies have found no difference in success
rates between the genders (Vangeli et al., 2011) so it may be the case that women who
seek help with stopping have greater difﬁculty than men who seek help with stopping.
Number of cigarettes smoked per day, time between waking and the ﬁrst cigarette
of the day and rated strength of urges to smoke prior to a quit attempt have been found
to predict success of quit attempts (Vangeli et al., 2011).
Quit attempts that involve gradual reduction are less likely to succeed than those
that involve quitting abruptly, even after controlling statistically for measures of
cigarette addiction, conﬁdence in quitting, other methods used to quit (e.g. nicotine
replacement therapy) and sociodemographic factors (Lindson-Hawley et al., 2016).
Interventions to combat smoking
There is extensive evidence on interventions that can reduce smoking prevalence, either
by reducing initiation or promoting cessation. Table 3 lists those that have the strongest
evidence.
Population-level interventions
Increasing the ﬁnancial cost of smoking through tax increases and control of illicit sup-
ply on average reduces overall consumption with a typical price elasticity globally of
0.4 (meaning that for every 10% increase in the real cost there is a 4% decrease in the
number of cigarettes purchased). Most of the effect is in getting smokers to reduce their
daily cigarette consumption so the effect on smoking prevalence has been found to be
an average of a 1–2 percentage point prevalence reduction for every 10% increase in
the real cost (Levy, Huang, Havumaki, & Meza, 2016). It has been claimed that
increasing taxes on tobacco increases the amount of smuggling of cheap tobacco, but
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the evidence does not support this (Action on Smoking and Health, 2015a; Joossens &
Raw, 2003).
Social marketing campaigns (e.g. TV advertising) can prevent smoking uptake,
increase the rate at which smokers try to quit and improve the chances of success. This
can lead to a reduction in smoking prevalence. Their effectiveness varies considerably
with intensity, type of campaign and context (Bala, Strzeszynski, Topor-Madry, &
Cahill, 2013; Hoffman & Tan, 2015).
Legislating to ban smoking in all indoor public areas may have a one-off effect on
reducing smoking prevalence but ﬁndings are inconsistent across different countries
(Bala et al., 2013). For example, in countries such as France it was not possible to
detect an effect while in England, there did appear to be a decline in prevalence follow-
ing the ban.
Although it is hard to show conclusively, circumstantial evidence suggests that
banning tobacco advertising and putting large graphic health warnings on cigarette
packets may have reduced smoking prevalence in some countries (Hoffman & Tan,
2015; Noar et al., 2016).
Individual-level interventions to promote smoking cessation
Brief advice
Brief advice to stop smoking from a physician and offer of support to all smokers,
regardless of motivation to quit, has been found in randomised trials to increase rate of
quitting by an average of 2 percentage points of all those receiving it, whether or not
Table 3. Effective interventions for combating smoking.
Intervention Effectiveness
Increasing the ﬁnancial cost through increasing
excise duty and reducing illicit supply
1–2 percentage point reduction in prevalence for
10% increase in cost of smoking; increases
cessation and reduces initiation
Anti-tobacco marketing campaigns Effect on cessation and initiation varies with
content and intensity of campaigns
Brief physician advice to smokers 1–3 percentage point increase in long-term
smoking cessation rate in all those receiving it
regardless of initial motivation to quit
Prescription for varenicline, nicotine
replacement therapy, bupropion,
nortriptyline or cytisine
5–15 percentage point increase in quit success
in those using it to try to quit (highest with
varenicline and nicotine patches plus faster
acting nicotine replacement therapy)
Behavioural support, either face to face or by
telephone
3–10 percentage point increase in long-term quit
success among those using it to try to quit for
multi-session support delivered by trained
specialists, the effect apparently being additive
with pharmacotherapy
Printed self-help materials 1–2 percentage point increase in long-term quit
success in those using it to try to quit compared
with nothing
Peer-led school-based anti-smoking
programmes and social competence training
Reduction in youth uptake varies with content
and intensity of the programme
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they were initially interested in quitting (Stead et al., 2013). The offer of support
appears to be more effective in getting smokers to try to quit than just advising smokers
to stop (Aveyard, Begh, Parsons, & West, 2012).
Pharmacotherapy
Using a form of nicotine replacement therapy (NRT: transdermal patch, chewing gum,
nasal spray, mouth spray, lozenge, inhalator, dissolvable strip) for at least 6 weeks from
the start of a quit attempt increases the chances of long-term success of that quit
attempt by about 3–7 percentage points if the user is under the care of a health profes-
sional or provided as part of a structured support programme (Stead et al., 2012). Some
studies have found that NRT when bought from a shop and used without any additional
structured support does not improve the chances of success at stopping (Kotz, Brown,
& West, 2014a, 2014b). A small proportion of people who use NRT to stop smoking
continue to use it for months or even years after stopping smoking, but NRT appears to
carry minimal risk to long-term users (Royal College of Physicians, 2016; Stead et al.,
2012).
Data are sparse but at present, using an electronic cigarette in a quit attempt appears
to increase the chances of success at stopping on average by an amount broadly similar
to that from NRT; the variety of products available and the greater similarity to smok-
ing appear to make them more attractive to many smokers as a means of stopping than
NRT (McNeill et al., 2015; Royal College of Physicians, 2016). Electronic cigarettes
deliver nicotine to users by heating a liquid containing nicotine, propylene glycol or
glycerol and usually ﬂavourings to create a vapour that is inhaled. They appear to carry
minimal acute risk to users. If they are used long-term, their risk is almost certainly
much less than that of smoking (based on concentrations of chemicals in the vapour)
(McNeill et al., 2015; Royal College of Physicians, 2016).
‘Dual-form NRT’ (combining a transdermal NRT patch and one of the other forms)
increases the chances of success at stopping more than ‘single-form NRT’ ( just using
one of the products) (Stead et al., 2012). Starting to use a nicotine transdermal patch
several weeks before the target quit date may improve the chances of success at quitting
compared with starting on the quit date (Stead et al., 2012).
Taking the prescription anti-depressant, bupropion (brand name Zyban), improves
the chances of success of quit attempts by a similar amount to single-form NRT
(Hughes, Stead, Hartmann-Boyce, Cahill, & Lancaster, 2014). Bupropion often leads to
sleep disturbance and carries a very small risk of seizure. Bupropion probably works by
reducing urges to smoke rather than any effect on depressed mood, but how it does this
is not known. It is contra-indicated in pregnant smokers and people with an elevated
seizure risk or history of eating disorder (Hughes et al, 2014). Taking the tricyclic anti-
depressant, nortriptyline also improves the chances of success of quit attempts, probably
by about the same amount as bupropion and NRT (Hughes et al., 2014). Its mechanism
of action is not known. Nortriptyline often leads to dry mouth and sleep disorder and
can be fatal in overdose (Hughes et al., 2014).
Taking the nicotinic-acetylcholine receptor partial agonist, varenicline (brand name
Chantix in the US and Champix elsewhere), improves the chances of success by about
50% more than bupropion or single-form NRT (Cahill, Lindson-Hawley, Thomas,
Fanshawe, & Lancaster, 2016). This is true for smokers with or without a psychiatric
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disorder (Anthenelli et al., 2016). Varenicline appears to work both by reducing urges
to smoke and the rewarding effect of nicotine should a lapse occur (West, Baker,
Cappelleri, & Bushmakin, 2008). Varenicline often leads to sleep disturbance and
nausea. Serious neuropsychiatric and cardiovascular adverse reactions have been
reported, but in comparative studies these have not been found to be more common
than placebo or NRT (Anthenelli et al., 2016; Cahill et al., 2016; Sterling, Windle,
Filion, Touma, & Eisenberg, 2016).
Taking the nicotinic-acetylcholine receptor partial agonist, cytisine, appears to
improve the chances of success at least as much as single-form NRT and probably more
(Cahill et al., 2016). Cytisine often causes nausea. No serious adverse reactions have
been reported to date (Cahill et al., 2016). Where it is licensed for sale, cytisine is less
than 1/10th the cost of other smoking cessation medications (Cahill et al., 2016).
Behavioural support
There is good evidence that behavioural interventions of many kinds, delivered though
several modalities can help smokers to stop. Thus, behavioural support (encouragement,
advice and discussion) from a trained stop-smoking specialist, provided at least weekly
until at least 4 weeks following the target quit date can increase the chances of long-
term success of a quit attempt by about 3–7 percentage points, whether it is given by
phone or face-to-face (Lancaster & Stead, 2005). Group behavioural support (specialist-
led groups of smokers stopping together and engaging in a structured discussion about
their experiences), involving at least weekly sessions lasting until at least 4 weeks after
the target quit date can increase the chances of success of a quit attempt by a similar
amount or possibly more than individual support (Stead & Lancaster, 2005). Scheduled,
multi-session telephone support can improve rates of success at stopping smoking by a
broadly similar amount (Stead, Hartmann-Boyce, Perera, & Lancaster, 2013) but some
large studies have failed to detect an effect so contextual factors and/or the precise type
of support could be crucial to success. The effects of behavioural support and medica-
tion/NRT on success at stopping smoking appear to combine roughly additively (Stead,
Koilpillai, & Lancaster, 2015). Smoking cessation support appears to be effective in pri-
mary care, secondary care and worksite settings (Cahill & Lancaster, 2014; West et al.,
2015). Financial incentives, in the form of vouchers, have been found to increase smok-
ing cessation rates for as long as they are in place (Cahill, Hartmann-Boyce, & Perera,
2015; Higgins & Solomon, 2016). Printed self-help materials can improve the chances
of success at stopping long term by around 1–2 percentage points (Hartmann-Boyce,
Lancaster, & Stead, 2014).
There is still relatively limited evidence on the effectiveness of digital support inter-
ventions for smoking cessation. Thus, while there is evidence that tailored, interactive
websites can improve the chances of success at stopping smoking compared with no
support, brief written materials or static information websites, many of those tested have
not been found to be effective and it is not clear what differentiates those that are effec-
tive from those that are not (Graham et al., 2016). Text messaging programmes have
been found to increase the chances of success of quit attempts by about 2–7 percentage
points (Whittaker, McRobbie, Bullen, Rodgers, & Gu, 2016). There is currently insufﬁ-
cient evidence to know whether smartphone applications can improve success rates of
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quit attempts, although preliminary data suggest that they might (Whittaker et al.,
2016). Evidence on alternative and complementary therapies is not sufﬁcient to make
conﬁdent statements about their effectiveness as aids to smoking cessation (Barnes
et al., 2010; White, Rampes, Liu, Stead, & Campbell, 2014).
Overall, the highest smoking cessation rates appear to be achieved using specialist
face-to-face behavioural support together with either varenicline or dual form NRT.
With this support, continuous abstinence rates up to 52 weeks, veriﬁed by expired-air
carbon monoxide tests, of more than 40% have been achieved (Kralikova et al., 2013).
More commonly, 52-week continuous abstinence rates with this treatment are between
15 and 25% (West et al., 2015).
Smoking cessation support for pregnant smokers
In pregnant smokers, there is some evidence that NRT can help promote smoking cessa-
tion but evidence for an effect sustained to end of pregnancy is not conclusive (Sterling
et al., 2016). There is also evidence that written self-help materials and face-to-face
behavioural support can aid smoking cessation (Jones, Lewis, Parrott, Wormall, &
Coleman, 2016), and ﬁnancial incentives have also been found to improve quitting rates
among pregnant smokers (Tappin et al., 2015). Almost half of women who stop smok-
ing during pregnancy as a result of a clinical intervention relapse to smoking within
6 months of the birth (Jones et al., 2016).
Effectiveness of programmes to reduce smoking uptake
School-based programmes that involve both social competence training and peer-led
social inﬂuence have been found to reduce smoking uptake (Georgie, Sean, Deborah,
Matthew, & Rona, 2016) but educational programmes have not (Thomas, McLellan, &
Perera, 2013). Mass media campaigns and increasing the ﬁnancial cost of smoking
reduce smoking uptake (Brinn, Carson, Esterman, Chang, & Smith, 2012; van Hasselt
et al., 2015).
Reducing the harm from tobacco and nicotine use
Smokers who report that they are reducing their cigarette consumption smoke only 1–2
fewer cigarettes per day on average than when they say they are not (Beard et al.,
2013). Clinical trials have found that use of NRT while smoking can substantially
reduce cigarette consumption compared with placebo (Royal College of Physicians,
2016) but national surveys show very little reduction in cigarette consumption when
smokers take up use of NRT in real-world settings (Beard et al., 2013). The beneﬁt
from using NRT while continuing to smoke appears to be in promoting subsequent
smoking cessation. Using NRT (or varenicline) to reduce cigarette smoking with no
immediate plans to quit leads to increased rates of quitting subsequently (Wu, Sun, He,
& Zeng, 2015).
‘Snus’, a form of tobacco that is placed between the gums and the cheek and which
is prepared in a way that is very low in carcinogens, gives high doses of nicotine but
without evidence of an increase in risk of major tobacco-related cancers and either no, or
a small, increase in risk of heart disease. It does appear to increase risk of periodontal
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disease, however. Snus is very popular in Sweden. Sweden has very low rates of
smoking and tobacco-related disease indicating that a form of nicotine intake other than
smoking can become popular and suggesting that this can contribute to a substantial
reduction in tobacco-related harm (Royal College of Physicians, 2016).
The introduction of complete bans on smoking in indoor public areas can also be
considered as a harm reduction measure. In this case, the main issue is harm to
non-tobacco users. The evidence shows that such bans have been rapidly followed in
the UK and several other jurisdictions by a reduction in heart attacks in non-smokers
(Action on Smoking and Health, 2014a).
Conclusions
Tobacco smoking causes death and disability on a huge scale and only about half of
smokers report enjoying it. Despite this, approximately 1 billion adults engage in this
behaviour worldwide and only around 5% of unaided quit attempts succeed for
6 months or more. The main reason appears to be that cigarettes deliver nicotine rapidly
to the brain in a form that is convenient, and palatable. Nicotine acts on the brain to
create urges to smoke in situations where smoking would normally occur and when
brain nicotine levels become depleted. Concern about the harm from, and ﬁnancial cost
of, smoking are mostly not sufﬁcient to counter this.
Governments can reduce smoking prevalence by raising the cost of smoking
through taxation, mounting sustained social marketing campaigns, ensuring that health
professionals routinely advise smokers to stop and offer support for quitting, and make
available pharmacological and behavioural support for stopping.
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